Plaque-Derived FFRCT
Hemodynamically significant coronary artery disease
Under DevelopmentActive
Key Facts
Indication
Hemodynamically significant coronary artery disease
Phase
Under Development
Status
Active
Company
About Elucid
Elucid is a commercial-stage diagnostics company leveraging AI and machine learning to transform the assessment of cardiovascular disease. Its core technology, PlaqueIQ, provides a non-invasive 'CT Virtual Histology' that quantifies plaque composition with high correlation to pathological gold standards, addressing the critical need to identify high-risk plaque that leads to heart attacks and strokes. With recent broad reimbursement from CMS and a new CPT code, the company is positioned for significant adoption. Elucid is also developing a plaque-derived FFRCT (Fractional Flow Reserve from CT) product to further integrate functional and morphological assessment.
View full company profileTherapeutic Areas
Other Hemodynamically significant coronary artery disease Drugs
| Drug | Company | Phase |
|---|---|---|
| DEEPVESSEL FFR | Keya Medical | Approved |